PE20020348A1 - Exemestano como agente quimiopreventivo - Google Patents

Exemestano como agente quimiopreventivo

Info

Publication number
PE20020348A1
PE20020348A1 PE2001000890A PE2001000890A PE20020348A1 PE 20020348 A1 PE20020348 A1 PE 20020348A1 PE 2001000890 A PE2001000890 A PE 2001000890A PE 2001000890 A PE2001000890 A PE 2001000890A PE 20020348 A1 PE20020348 A1 PE 20020348A1
Authority
PE
Peru
Prior art keywords
inhiborine
compound
chemopreventive agent
exemestane
exemestan
Prior art date
Application number
PE2001000890A
Other languages
English (en)
Inventor
Salle Enrico Di
Alesandro Martini
Dinesh Purandare
Lorena Muggetti
Gabriella Piscitelli
Giorgio Massimini
Original Assignee
Pharmacia & Upjohn Spa
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa, Upjohn Co filed Critical Pharmacia & Upjohn Spa
Publication of PE20020348A1 publication Critical patent/PE20020348A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Abstract

SE REFIERE AL USO DEL COMPUESTO 6-METILENANDROST-1,4-DIENO-3,17-DIONA CONOCIDO COMO EXEMESTANO PARA EL TRATAMIENTO DE CANCER ESTROGENO DEPENDIENTE. LA DOSIS DEL COMPUESTO POR VIA ORAL ES DE 10mg A 50mg Y POR VIA INTRAMUSCULAR ES DE 50mg A 600mg. EL COMPUESTO EXEMESTANO ES INHIBIDOR DE LA AROMATASA Y PUEDE SER ADMINISTRADO EN FORMA SIMULTANEA CON OTRO AGENTE QUIMIOPREVENTIVO SELECCIONADO DE TAXANO, UN COMPUESTO ANTIINFLAMATORIO NO ESTEROIDE, UN COMPUESTO RETINOIDE, UN INHIBIDOR DE LA FARNESILTRANSFERASA, UN INHIBIDOR DE LA METALOPROTEASA, UN INHIBIDOR DE LA PROTEINA CINASA, ENTRE OTROS
PE2001000890A 2000-09-08 2001-09-05 Exemestano como agente quimiopreventivo PE20020348A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65805200A 2000-09-08 2000-09-08

Publications (1)

Publication Number Publication Date
PE20020348A1 true PE20020348A1 (es) 2002-04-18

Family

ID=24639711

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000890A PE20020348A1 (es) 2000-09-08 2001-09-05 Exemestano como agente quimiopreventivo

Country Status (15)

Country Link
US (1) US20040024044A1 (es)
EP (1) EP1317270A1 (es)
JP (1) JP2004508334A (es)
KR (1) KR20030043955A (es)
CN (1) CN1729002A (es)
AR (1) AR034150A1 (es)
AU (2) AU8986501A (es)
BR (1) BR0113625A (es)
CA (1) CA2419590A1 (es)
MX (1) MXPA03001983A (es)
MY (1) MY137766A (es)
NZ (1) NZ524104A (es)
PE (1) PE20020348A1 (es)
WO (1) WO2002020020A1 (es)
ZA (1) ZA200301309B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
GB0017635D0 (en) * 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
US6903121B1 (en) 2000-08-17 2005-06-07 Allergan, Inc. Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
BR0116575A (pt) * 2001-01-09 2004-01-06 Merck Patent Gmbh Terapia combinada que usa inibidores de tirosina cinase receptora e inibidores de angiogênese
MXPA03006607A (es) * 2001-01-26 2003-09-22 Upjohn Co Metodo combinado para tratar trastornos dependientes de hormonas.
DE10154464B4 (de) * 2001-11-08 2005-10-20 Max Delbrueck Centrum Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes Taxol
ES2279441T3 (es) 2003-09-19 2007-08-16 Astrazeneca Ab Derivados de quinazolina.
AU2006213659A1 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting HER2 shedding with matrix metalloprotease antagonists
CA2605796A1 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
CA2628747C (en) * 2005-11-22 2014-01-21 Incyte Corporation Combinations of hormone therapy agents and metalloprotease inhibitors for the treatment of cancer
TW200800177A (en) * 2006-02-14 2008-01-01 Wyeth Corp Aqueous pharmaceutical formulations of ERβ selective ligands
CN101410012A (zh) * 2006-03-28 2009-04-15 杰佛林制药公司 低剂量的非甾体抗炎药和β-环糊精的制剂
WO2007112272A2 (en) * 2006-03-28 2007-10-04 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
CA2649620A1 (en) * 2006-04-24 2007-11-01 Panacea Biotec Ltd. Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof
CA2700664A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and aromatase inhibitors or combinations of cox-2 inhibitors and estrogen receptor antagonists
CN101468023B (zh) * 2007-12-26 2011-02-02 上海复星医药（集团）股份有限公司 依西美坦片及其制备工艺
KR100925811B1 (ko) * 2007-12-28 2009-11-06 주식회사 지에스메디칼 척추 고정기구
CN102939287B (zh) 2010-06-10 2016-01-27 塞拉根制药公司 ***受体调节剂及其用途
EP2616078B1 (en) 2010-09-16 2019-12-25 Shimoda Biotech (Pty) Ltd Fulvestrant compositions and methods of use
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
HUE063437T2 (hu) 2013-09-24 2024-01-28 Fujifilm Corp Nitrogént tartalmazó vegyületet vagy sóját vagy fémkomplexét tartalmazó gyógyászati készítmény
RU2729518C2 (ru) 2015-12-30 2020-08-07 Сент-Луис Юниверсити Мета-азациклические производные аминобензойной кислоты в качестве антагонистов пан-интегрина
TWI639430B (zh) * 2016-08-27 2018-11-01 中國醫藥大學 醫藥組合物用於製備治療胃癌藥物的用途
CN114948901B (zh) * 2022-05-06 2023-04-21 郑州大学第一附属医院 一种协同治疗乳腺癌的依西美坦纳米粒、制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
IL143901A0 (en) * 1998-12-23 2002-04-21 Searle & Co Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
GB9911582D0 (en) * 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
GB0005257D0 (en) * 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy

Also Published As

Publication number Publication date
US20040024044A1 (en) 2004-02-05
BR0113625A (pt) 2003-07-22
MY137766A (en) 2009-03-31
NZ524104A (en) 2004-12-24
CN1729002A (zh) 2006-02-01
KR20030043955A (ko) 2003-06-02
WO2002020020A1 (en) 2002-03-14
JP2004508334A (ja) 2004-03-18
AU8986501A (en) 2002-03-22
AR034150A1 (es) 2004-02-04
MXPA03001983A (es) 2003-06-24
ZA200301309B (en) 2004-02-18
AU2001289865B2 (en) 2007-03-01
EP1317270A1 (en) 2003-06-11
CA2419590A1 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
PE20020348A1 (es) Exemestano como agente quimiopreventivo
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
PA8523201A1 (es) Nueva composicion farmaceutica
CR7877A (es) Derivados de 4-tetrazolil-4-fenilpiperidina para tratar el dolor
UY26977A1 (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
GT200500102A (es) Compuestos de aril-o-heteroarilamida ortosustituidos
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
PE20060464A1 (es) Composicion farmaceutica que comprende flibanserina para el tratamiento de trastornos sexuales
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
ECSP066972A (es) Profármacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y métodos
UY28287A1 (es) Combinaciones para el tratamiento de enfermedades que impican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
PA8588601A1 (es) Administracion combinada de una indolinona junto a un agente quimioterapeutico para el tratamiento de enfermedades de proliferacion celular
PE20020909A1 (es) Una combinacion que comprende combretastatina y agentes anticancerigenos
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
BRPI0506977A (pt) composto de tetrahidrocarbolina como agentes anticáncer
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
DE60309895D1 (de) Estrogenersatztherapie
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
AR109263A2 (es) Composición que comprende moxidectina
ES2188426B1 (es) Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
SV2002000969A (es) Composicion parenteral reconstituible
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple

Legal Events

Date Code Title Description
FC Refusal